Showing results (41-50 of 1,410) with videos related to
Sort By:
Pageof 141
NPJ Precision Oncology|July 2, 2025
Progress and challenges of artificial intelligence in lung cancer clinical translationErjia Zhu, Amgad Muneer, Jianjun Zhang, et al.Carcinogenesis|February 11, 2017
Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapyRong Li, Jiang Gu, John V Heymach, et al.Clinical Lung Cancer|September 22, 2024
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung CancerKyle F Concannon, Bonnie S Glisson, Robert C Doebele, et al.Journal of Intensive Care Medicine|November 17, 2021
Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center ReportFelippe Lazar Neto, Luana G Sousa, Whitney E Lewis, et al.Cancer|March 13, 2010
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acidPeter E Zage, Lizhi Zeng, Shana Palla, et al.International Journal of Cancer|April 18, 2025
Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility statusSara Nofal, Edwin J Ostrin, Jianjun Zhang, et al.Lung Cancer (Amsterdam, Netherlands)|November 28, 2017
Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapyJie Shen, Yuanqing Ye, David W Chang, et al.Future Oncology (London, England)|February 17, 2025
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLCJohn V Heymach, Helena A Yu, Benjamin Besse, et al.Expert Review of Anticancer Therapy|February 5, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside reviewJohn V Heymach, Sanjay Popat, Egbert F Smit, et al.Cancer|February 21, 2013
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapyVikas Bhardwaj, Tina Cascone, Maria Angelica Cortez, et al.Pageof 141